History

Mesterolone was first described around 1966 and introduced for medical use by Schering as Proviron by 1967. In Europe and elsewhere it was marketed for male hypogonadism/androgen deficiency and, more controversially, for idiopathic male infertility — a use the controlled evidence does not support. It was never marketed and never FDA-approved in the United States (and is not approved in Canada). Despite never being a US-approved drug, it is a Schedule III controlled substance in the US as an anabolic steroid under the Anabolic Steroid Control Act/Controlled Substances Act.

Mesterolone, almost always known by the brand name Proviron, is a synthetic, orally active anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). It is an androgen — not a peptide and not a SARM. Unlike most of the other agents people lump it in with, mesterolone was never approved or marketed in the United States, so the common framing that “these are mostly approved drugs” does not apply here. Its medical history abroad centered on male hypogonadism and idiopathic male infertility, but controlled human trials for its two historically promoted uses (fertility and mood) are negative or unconvincing, and its bodybuilding reputation as an “anti-estrogen” or “free-testosterone raiser” has no strong human evidence behind it. This profile reports no doses, cycles, stacks, or post-cycle protocols — it is a reference, not a how-to.

What it is

Mesterolone (INN) is a synthetic, orally active anabolic-androgenic steroid of the DHT family. Structurally it is 1α-methyl-DHT (1α-methyl-5α-androstan-17β-ol-3-one) — dihydrotestosterone with a methyl group added at the C1α position. That 1α-methyl group confers oral bioavailability by resisting first-pass metabolism, and importantly it means the compound is not 17α-alkylated. 17α-alkylation is the modification responsible for the classic liver toxicity of oral steroids such as methyltestosterone and stanozolol; because mesterolone lacks it, it does not carry that overt hepatotoxic signature.

Mechanistically, mesterolone is an agonist at the androgen receptor (AR). As a 5α-reduced DHT derivative it is not a substrate for aromatase, so it does not convert to estrogen and has no direct estrogenic effects. That non-aromatizing property, combined with its high binding affinity for sex hormone-binding globulin (SHBG), is the basis of its informal reputation as an “anti-estrogen” or “free-testosterone raiser” — though robust clinical data for that effect are weak. In overall profile it is strongly androgenic relative to its modest anabolic activity, so it is not used to build large amounts of lean mass.

The claims

Medical (outside the US): historical/occasional support for androgen deficiency, and — more controversially — treatment of idiopathic male infertility (oligospermia), a use that controlled evidence does not support.
Physique/performance (off-label, illicit): that mesterolone’s SHBG binding raises “free testosterone,” acts as an “anti-estrogen,” boosts libido, and produces a “harder” look — rather than building mass.

None of these performance uses are supported by an approved indication or by strong human efficacy data.

What the evidence actually shows

Male infertility — it does not clearly work. A double-blind, placebo-controlled trial of high-dose mesterolone in idiopathic male infertility (Gerris et al., Fertil Steril 1991) found the pregnancy rate was actually lower in the mesterolone group than placebo (about 26% vs 48%); semen-parameter improvements occurred in the placebo arm too, and the authors concluded their data “cast doubt on” any usefulness of the treatment. A larger double-blind, placebo-controlled study by the WHO Task Force (Int J Androl 1989) found only a small, statistically non-significant trend in pregnancy rate (placebo 9% vs 12% vs 16% across groups, with wide overlapping confidence intervals) and no meaningful improvement in semen quality — i.e., no established fertility benefit. Older uncontrolled case series (e.g., Guillon, 1975, reporting subjective improvement in a minority of 141 patients) lacked controls and are contradicted by the controlled trials above.

Depression / mood — no benefit over placebo. A double-blind, placebo-controlled study of mesterolone in 52 depressed men (Itil et al., Methods Find Exp Clin Pharmacol 1984) found symptom improvement that was not statistically distinguishable from placebo; mesterolone also lowered testosterone levels. This is consistent with the broader androgen-for-depression literature — for example, a testosterone replacement RCT in hypogonadal depressed men (Seidman et al., J Clin Psychiatry 2001) found the antidepressant effect “could not be differentiated from” placebo.

Performance / “anti-estrogen” claims. There is no strong human evidence for the SHBG-mediated “free-testosterone,” “anti-estrogen,” or “hardening” effects that drive its physique-circle popularity.

The net picture: for its two historically promoted indications (fertility and mood), controlled human evidence is negative or unconvincing, and there is no credible human evidence supporting the performance claims.

Legal and regulatory status

In the United States, mesterolone is a Schedule III controlled substance as an anabolic steroid under the Anabolic Steroid Control Act/Controlled Substances Act, even though it was never marketed or FDA-approved here (and is not approved in Canada). Non-prescription possession or distribution is a federal offense. For context on the compounds it is often grouped with: fluoxymesterone is likewise a Schedule III anabolic steroid; aromatase inhibitors (anastrozole, letrozole, exemestane) and SERMs (tamoxifen, clomiphene, raloxifene) are legitimate prescription drugs (not controlled substances) approved for oncology/endocrine/fertility uses, with any performance-support use being off-label; T3 (liothyronine) and insulin are prescription drugs (not controlled) approved for hypothyroidism and diabetes respectively, with performance use off-label and dangerous; and DNP (2,4-dinitrophenol) is not approved for human consumption at all — the FDA deemed it “unfit for human consumption” after 1930s diet-pill poisonings, and it is an industrial chemical illegally sold online as a “fat burner” with an ongoing record of fatalities.

In sport, mesterolone is prohibited at all times (in- and out-of-competition) as an anabolic agent under WADA Class S1 on the 2026 Prohibited List. For comparison: aromatase inhibitors and anti-estrogens/SERMs fall under S4 (Hormone and Metabolic Modulators) — S4.1 aromatase inhibitors and S4.2 anti-estrogenic substances/SERMs; insulins and insulin-mimetics fall under S4.4 (metabolic modulators); generic metabolic modulators also sit under S4.4; and T3/thyroid hormone is not on the WADA Prohibited List.

Safety

Mesterolone carries the standard androgen-class harms, even though it avoids the overt hepatotoxicity of 17α-alkylated orals.

Androgenic effects: acne, oily skin, and accelerated male-pattern hair loss in predisposed men. In women it can cause virilization (voice deepening, hirsutism, clitoral enlargement) that is partly irreversible.
HPG-axis suppression: like other exogenous androgens, it suppresses the hypothalamic-pituitary-gonadal axis and endogenous testosterone production.
Cardiovascular / lipids: adverse shifts in blood lipids (notably lowered HDL), with potential cardiovascular and prostate effects from androgen exposure.
Hepatotoxicity: lower than the 17α-alkylated orals because it is not 17α-alkylated — but this does not make it “safe.”
Unregulated supply: illicit products are unregulated and frequently mislabeled or contaminated.

Because mesterolone is usually discussed alongside other, far more dangerous performance compounds, the honest harm picture for those co-agents matters too:

DNP (2,4-dinitrophenol): a mitochondrial uncoupler that causes uncontrolled hypermetabolism and fatal hyperthermia (core temperatures reported up to about 44 °C / 111 °F), tachycardia, metabolic acidosis, and cardiac arrest. There is no specific antidote — treatment is symptomatic and aggressive cooling — and overdoses are frequently fatal. DNP kills people. It is the most dangerous compound in this group.
Insulin: non-diabetic misuse can cause lethal hypoglycemia — coma, irreversible brain injury, and death, sometimes rapidly and without warning.
Aromatase inhibitors: crashing estrogen harms bone mineral density and worsens lipids/cardiovascular risk; joint pain and mood effects are common.
SERMs (e.g., tamoxifen): carry thromboembolic risk (DVT/PE), plus visual and hepatic effects.
T3 (liothyronine): induces a hyperthyroid state — tachycardia/arrhythmia, cardiac strain, bone loss, muscle catabolism, and suppression of the endogenous thyroid axis that may not normalize promptly on stopping.

Bottom line

Mesterolone is an old, DHT-derived oral androgen that was sold abroad as Proviron for hypogonadism and idiopathic male infertility but was never approved or marketed in the United States. For its two historically promoted uses, controlled human trials are negative or unconvincing: a placebo-controlled fertility trial showed worse pregnancy rates than placebo, a larger WHO study found no meaningful fertility or semen benefit, and a controlled depression study showed no benefit over placebo. Its bodybuilding “anti-estrogen / free-testosterone” reputation rests on its non-aromatizing, SHBG-binding chemistry rather than on credible human evidence. It is a US Schedule III controlled substance, banned at all times in sport, and carries the full androgen-class risk profile despite avoiding 17α-alkylated liver toxicity. And among the compounds it travels with, DNP and insulin are genuinely lethal.

Evidence grade: No credible evidence.

Mesterolone (Proviron)